Go Deep
Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,935 | 15.8 | 1.47 | 0.90 | 2,571.18 |
| Oct 2026 | 20,599 | 15.8 | 1.48 | 0.90 | 2,562.02 |
| Oct 2026 | 21,188 | 15.4 | 1.44 | 0.90 | 2,480.84 |
| Oct 2026 | 21,182 | 15.4 | 1.44 | 0.90 | 2,476.23 |
| Oct 2026 | 21,114 | 15.6 | 1.46 | 0.90 | 2,508.87 |
| Oct 2026 | 21,223 | 15.3 | 1.43 | 0.90 | 2,450.28 |
| Oct 2026 | 21,170 | 15.5 | 1.45 | 0.90 | 2,478.50 |
| Oct 2026 | 21,209 | 15.3 | 1.44 | 0.90 | 2,459.54 |
| Oct 2026 | 21,158 | 15.5 | 1.45 | 0.90 | 2,478.05 |
| Oct 2026 | 21,190 | 15.4 | 1.44 | 0.90 | 2,457.94 |
Amphastar Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 183,903,000.0 | 171,171,000.0 | 183,105,000.0 | 191,840,000.0 |
| Net Profit | 30,348,000.0 | 6,420,000.0 | 24,429,000.0 | 17,350,000.0 |
| EPS | 0.7 | 0.1 | 0.5 | 0.4 |
Amphastar Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 719,887,000.0 | 731,967,000.0 | 644,395,000.0 | 498,987,000.0 | — |
| Net Profit | 98,094,000.0 | 159,519,000.0 | 137,545,000.0 | 91,386,000.0 | — |
| EPS | 2.1 | 3.3 | 2.9 | 1.9 | — |
Amphastar Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 1,629,299,000.0 | 1,577,470,000.0 | 1,512,912,000.0 | 741,987,000.0 | — |
| Total Liabilities | 840,494,000.0 | 845,172,000.0 | 873,491,000.0 | 213,329,000.0 | — |
| Total Equity | 788,805,000.0 | 732,298,000.0 | 639,421,000.0 | 528,658,000.0 | — |
Owes vs Owns
Amphastar Pharmaceuticals, Inc. owed $0.56 for every $1 it owned in Jun 2026, up from $0.29 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.56× | 0.52× | 0.54× | 0.58× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Amphastar Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 17.4%Receivables 9.9%Inventory 10.9%Fixed assets (tangible) 21.7%Intangible assets 34.7%Other assets 5.5%
How it's funded — Dec 2025
Long-term debt 37.4%Payables 2.0%Other liabilities 12.1%Shareholders' equity 48.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 282.8 | 221.6 | 256.8 | 175.8 |
| Receivables | 160.7 | 138.0 | 115.5 | 89.0 |
| Inventory | 176.9 | 153.7 | 105.8 | 103.6 |
| Fixed assets (tangible) | 353.7 | 344.6 | 315.6 | 264.6 |
| Intangible assets | 566.0 | 590.7 | 613.3 | 37.3 |
| Long-term investments | 0.0 | 11.0 | 15.2 | 2.4 |
| Other assets | 89.2 | 117.8 | 90.7 | 69.4 |
| Liabilities & equity | ||||
| Short-term debt | 1.6 | 0.2 | 0.4 | 3.0 |
| Long-term debt | 608.7 | 601.6 | 589.6 | 72.8 |
| Payables | 32.6 | 30.5 | 25.4 | 20.5 |
| Other liabilities | 197.5 | 212.8 | 258.0 | 116.9 |
| Shareholders' equity | 788.8 | 732.3 | 639.4 | 528.7 |
| Net tangible assets | 222.8 | 141.6 | 26.1 | 491.4 |
Amphastar Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 156,115,000.0 | 213,386,000.0 | 183,503,000.0 | 89,181,000.0 | — |
| Investing Activities | -70,332,000.0 | -124,930,000.0 | -649,116,000.0 | -32,777,000.0 | — |
| Financing Activities | -67,425,000.0 | -80,953,000.0 | 454,093,000.0 | -26,439,000.0 | — |